Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

BUY
$59.79 - $81.05 $658,945 - $893,252
11,021 Added 16.88%
76,316 $5.21 Million
Q4 2023

Feb 14, 2024

SELL
$45.35 - $63.41 $181,853 - $254,274
-4,010 Reduced 5.79%
65,295 $4.1 Million
Q3 2023

Nov 14, 2023

BUY
$46.0 - $53.1 $19,596 - $22,620
426 Added 0.62%
69,305 $3.53 Million
Q2 2023

Aug 14, 2023

BUY
$34.66 - $54.07 $559,862 - $873,392
16,153 Added 30.64%
68,879 $3.44 Million
Q1 2023

May 10, 2023

SELL
$36.27 - $47.2 $31,953 - $41,583
-881 Reduced 1.64%
52,726 $1.98 Million
Q4 2022

Feb 14, 2023

BUY
$20.58 - $47.95 $436,213 - $1.02 Million
21,196 Added 65.4%
53,607 $2.57 Million
Q3 2022

Nov 14, 2022

SELL
$21.69 - $28.53 $47,370 - $62,309
-2,184 Reduced 6.31%
32,411 $778,000
Q2 2022

Aug 11, 2022

BUY
$17.68 - $26.58 $611,639 - $919,535
34,595 New
34,595 $753,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $5.45B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Alps Advisors Inc Portfolio

Follow Alps Advisors Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

News

Stay updated on Alps Advisors Inc with notifications on news.